Patents Examined by C. Delacroix-Muirheid
  • Use of pramipexole for the treatment of addictive disorders
    Patent number: 6410579
    Abstract: This patent application describes the treatment addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and or nicotine addiction comprising administering a therapeutically effective, nontoxic dose of pramipexole and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Grant
    Filed: February 14, 2001
    Date of Patent: June 25, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Robert Clyde Marshall, Erik Ho Fong Wong, Philip F. Von Voigtlander
  • Glucagon-like insulinotropic peptides, compositions and methods
    Patent number: 6410513
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: June 25, 2002
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffman
  • Compounds and method for use thereof in the treatment of cancer or viral infections
    Patent number: 6407131
    Abstract: Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: June 18, 2002
    Assignee: The Procter & Gamble Company
    Inventors: James C. Quada, Jr., Joseph K. Agyin, James Berger Camden
  • Method for enhancing functional recovery following central nervous system ischemia or trauma
    Patent number: 6407060
    Abstract: The present invention provides methods and compositions for treatment of mammals afflicted with an ischemic or traumatic injury of the central nervous system. The present invention capitalizes in part upon the discovery that administration of a morphogen to such a mammal provides significant improvement in central nervous system function, even when administered after central nervous system tissue has been damaged. The methods involve the administration of dimeric proteins defined as morphogens, inducers of these morphogens, or agonists of the corresponding morphogen receptors, or implantation of cells stimulated by exposure to the morphogens. The proteins defined as morphogens comprise a structurally and functionally distinct family within the TGF-&bgr; superfamily. Osteogenic protein-1 (OP-1) is considered to be an exemplary and preferred member of this morphogen family.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: June 18, 2002
    Assignee: Curis, Inc.
    Inventors: Marc F. Charette, Seth P. Finklestein
  • Methods for altering hair growth and hair pigmentation by apoptosis in the follicular papillae and compositions therefor
    Patent number: 6407056
    Abstract: The present invention utilizes serine proteases and their ability to induce programmed cell death and apoptosis in the follicular papillae to affect changes in mammalian hair growth and hair pigmentation. Also described are compositions which have an agent with a portion of similar structure to a portion of the trypsin molecule, allowing said agent to induce programmed cell death and apoptosis in the same manner as trypsin.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: June 18, 2002
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Miri Seiberg, Stanley S. Shapiro, Gerard F. M. J. Cauwenbergh, Stephen J. Wisniewski
  • Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
    Patent number: 6403611
    Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: June 11, 2002
    Assignee: Pfizer Inc.
    Inventors: David B. Maclean, David D. Thompson
  • Photochemical gas-liquid process for halogenating alkylbenzenes
    Patent number: 6398922
    Abstract: The invention provides a process for carrying out a photochemical gas-liquid process for halogenating alkylbenzenes, the process being carried out in a photochemical gas-liquid reactor comprising a vessel, a central source of radiation, a gas distributor, and additionally, inner sleeve means arranged concentrically between the source of radiation and the vessel, the inner sleeve means providing for internal recirculation of reaction liquid.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: June 4, 2002
    Assignee: Elf Atochem S.A.
    Inventor: Gerard Desire
  • Process and system for wastewater solids gasification and vitrification
    Patent number: 6398921
    Abstract: A process for gasifying solid organic matter from wastewater sludge involves dewatering the sludge to a solids content of at least 35% by weight using a combination of centrifugation, microwave heat exchange and screw press separation. The denatured solids are than at least partially pyrolyzed by passing through a heated inclined screw auger. The pyrolysis solids, tars and gases are then gasified by exposure to a high intensity microwave field. Resulting fuel gas and char from the gasification are then separated, with the char then being combusted in a cyclonic char burner to produce vitrified ash and process heat. Fuel gases are cleaned and then burned in internal combustion engines for the generation of electricity and process heat.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: June 4, 2002
    Assignee: MicroGas Corporation
    Inventor: Dennis P. Moraski
  • Method of treating glaucoma and ischemic retinopathy
    Patent number: 6387904
    Abstract: A method for treating glaucoma and ischemic retinopathy in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of the formula or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined in the specification.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: May 14, 2002
    Assignee: Pfizer INC
    Inventor: Harry R. Howard
  • Glucagon-like insulinotropic peptides, compositions and methods
    Patent number: 6388053
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: May 14, 2002
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffmann
  • Cyclic peptide antifungal agents and process for preparation thereof
    Patent number: 6384013
    Abstract: Provided are compounds of the formula (1): wherein R′ is hydrogen, methyl or NH2C(O)CH2—; R″ and R′″ are independently methyl or hydrogen; R and Ry are independently hydroxy or hydrogen; R1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R2 is a acyl side chain. Also provided are formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R═H) forms of the compounds.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: May 7, 2002
    Assignee: Eli Lilly and Company
    Inventors: Frederick J. Burkhardt, Manuel Debono, Jeffrey S. Nissen, William W. Turner, Jr.
  • Lipopolysaccharide-binding and neutralizing peptides
    Patent number: 6384188
    Abstract: Substance which bind with high affinity to endotoxin (lipopolysaccharide [LPS]), and which are useful for the prevention or treatment of, for example, Gram-negative and Gram-positive bacterial sepsis, and for the treatment of bacterial and fungal infections as well as for neutralizing effects associated with heparin. The substances are LPS-binding peptides comprising an LPS-binding domain. DNA sequences encoding peptides, recombinant microorganisms containing the DNA, pharmaceutical compositions containing the peptides of the invention, and diagnostic kits. Methods for the detection and removal of bacterial LPS from solutions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 7, 2002
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Adolf Hoess, Robert C. Liddington, George R. Siber
  • Devices for cloaking transplanted cells
    Patent number: 6368612
    Abstract: Implantable devices that include a source of a therapeutic substance and a capture agent are disclosed.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: April 9, 2002
    Assignee: Biohybrid Technologies LLC
    Inventors: Robert P. Lanza, William Chick
  • Reverse prenyl compounds as immunosuppressants
    Patent number: 6355639
    Abstract: The present invention provides a method for treating a subject in need of immunosuppression, comprising administering to the subject an effective amount of a compound having structure (I) wherein R1, R6 and R7 are independently hydrogen, OH, NH2, SH, halogen, C1-C9 linear or branched chain alkyl, alkylmercapto, alkylamino, etc.; wherein R0 and R2 are independently hydrogen, OH, C1-C9 linear or branched chain alkyl, —CR3R3—CH(O)CH2, —CR3R3—CH═CHR4, etc.; wherein R3 and R4 are independently hydrogen halogen C1-C9 linear or branched chain alkyl, etc.; wherein R5 is hydrogen, C1-C9 linear or branched chain alkyl, phenyl, alkylphenyl, dialkylphenyl, alkylmercapto, etc.; and wherein R8 is hydrogen, C1-C9 linear or branched chain acyl, benzoyl, alkylbenzoyl, etc. Also provided are methods of treating autoimmune disease and preventing organ graft rejection using N-acetylardeemin and related compounds.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: March 12, 2002
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ting-Chao Chou, Joseph R. Bertino, Samuel J. Danishefsky, Barry D. Kahan
  • Method for reducing levels of homocysteine and C-reactive protein
    Patent number: 6353003
    Abstract: The current invention relates to a method for decreasing levels of homocysteine and/or C-reactive protein in humans comprising administering to a mammal in need thereof an effective amount of a compound of formula I: or a pharmaceutical salt or solvate thereof.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: March 5, 2002
    Assignee: Eli Lilly and Company
    Inventor: Pamela Wang Anderson
  • Oligopeptides derived from C-reactive protein fragments
    Patent number: 6342481
    Abstract: The present invention relates to oligopeptide derived from fragments of the C-reactive protein (CRP), and to their use in the therapy of cardiovascular and inflammatory diseases.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: January 29, 2002
    Assignee: Italfarmaco S.p.A.
    Inventors: Flavio Leoni, Silvio Agozzino, Paolo Mascagni
  • Cytoprotective effect of polycyclic phenolic compounds
    Patent number: 6319914
    Abstract: The invention comprises methods for conferring a cytoprotective effect on a population of cells, such as providing a polycyclic phenolic compound in a physiologically acceptable formulation, and administering the formulation in an effective dose to the population of cells.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: November 20, 2001
    Assignees: Apollo BioPharmaceuticals, Inc., University of Florida Research Foundation, Inc.
    Inventors: James W. Simpkins, Katherine D. Gordon, Pattie S. Green
  • Multi-carotenoid product
    Patent number: 6309677
    Abstract: A composition is provided that includes carotenoid extracts derived from a plurality of natural sources. Carotenoids are extracted from natural sources such as palm fruit, algae and marigold flowers and combined in a single product. The product may include carriers such as yellow bees wax, soybean oil and lecithin and may be in a form suitable for oral ingestion.
    Type: Grant
    Filed: March 24, 1998
    Date of Patent: October 30, 2001
    Assignee: Amway Corporation
    Inventors: David Gorenbein, Idrees A. Siddiqui, Ernie R. Ceja, Christine M. Horvath
  • Method of manufacturing semiconductor device
    Patent number: 6306761
    Abstract: A hard Al oxide film having a high melting point, which grows on the surface of an Al—Cu film during a wafer is carried in atmospheric air, obstructs the burying of a viahole with the Al—Cu film by high pressure reflow, with a result that a void remains in the hole. The present invention is intended to remove such an Al oxide film grown on the Al—Cu film formed by sputtering, by Ar+ sputtering/etching directly before high pressure reflow. Moreover, when a Ti oxide film is present on the surface of a Ti based underlying film formed by CVD, an Al oxide film is possibly grown at the boundary between the Ti based underlying film and an Al—Cu film laminated thereon. In this case, the Ti oxide film is similarly removed directly before formation of the Al—Cu film, thereby preventing the growth of the Al oxide film.
    Type: Grant
    Filed: April 25, 1996
    Date of Patent: October 23, 2001
    Assignee: Sony Corporation
    Inventor: Mitsuru Taguchi
  • Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
    Patent number: 6306437
    Abstract: Psychogenic impotence can be ameliorated without substantial undesirable side effects by administration of apomorphine and an antiemetic agent in an amount sufficient to substantially reduce nausea symptoms associated with the use of apomorphine.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: October 23, 2001
    Assignee: Pentech Pharmaceuticals, Inc.
    Inventors: Ragab El-Rashidy, Bruce Ronsen